HLA-A and acute myeloid leukemia: In the context of AML therapy, allo-restricted TCRs have been used to recognize HLA-A*02:01-restricted WT1126-134 peptide (NCT02550535) [52,53] and HLA-A*02:01-restricted PRAME peptides (NCT02743611) [57].